J
Jordi Remon
Researcher at Institut Gustave Roussy
Publications - 172
Citations - 5052
Jordi Remon is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 30, co-authored 150 publications receiving 3071 citations. Previous affiliations of Jordi Remon include Hebron University & Université Paris-Saclay.
Papers
More filters
Journal ArticleDOI
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F. Mosele,Jordi Remon,Joaquin Mateo,C. B. Westphalen,Fabrice Barlesi,Martijn P. Lolkema,Nicola Normanno,Aldo Scarpa,Mark E. Robson,Funda Meric-Bernstam,Nikhil Wagle,Albrecht Stenzinger,Julia Bonastre,A. Bayle,Stefan Michiels,Ivan Bièche,Etienne Rouleau,S. Jezdic,J.-Y. Douillard,Jorge S. Reis-Filho,R. Dienstmann,Fabrice Andre +21 more
TL;DR: ESMO recommends routine use of NGS on tumour samples in advanced non-squamous NSCLC, prostate cancers, ovarian cancers and cholangiocarcinoma, and develops multigene sequencing as a tool to screen patients eligible for clinical trials and to accelerate drug development.
Journal ArticleDOI
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Laura Mezquita,Edouard Auclin,Roberto Ferrara,Melinda Charrier,Jordi Remon,David Planchard,Santiago Ponce,L. Arés,L. Leroy,Clarisse Audigier-Valette,Enriqueta Felip,Jorge Zeron-Medina,Pilar Garrido,Solenn Brosseau,Gérard Zalcman,Julien Mazieres,Caroline Caramela,J. Lahmar,Julien Adam,Nathalie Chaput,Nathalie Chaput,Jean-Charles Soria,Jean-Charles Soria,Benjamin Besse,Benjamin Besse +24 more
TL;DR: Pretreatment LIPI, combining dNLR greater than 3 and LDH greater than upper limit of normal (ULN) was correlated with worse outcomes for ICI, but not for chemotherapy, suggesting that LIPi can serve as a potentially useful tool when selecting ICI treatment.
Journal ArticleDOI
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara,Laura Mezquita,M. Texier,J. Lahmar,Clarisse Audigier-Valette,Laurent Tessonnier,Julien Mazieres,Gérard Zalcman,Solenn Brosseau,Sylvestre Le Moulec,L. Leroy,Boris Duchemann,Corentin Lefebvre,Remi Veillon,Virginie Westeel,Serge Koscielny,Stéphane Champiat,Charles Ferté,David Planchard,Jordi Remon,Marie Eve Boucher,Anas Gazzah,Julien Adam,Emilio Bria,Giampaolo Tortora,Jean-Charles Soria,Benjamin Besse,Benjamin Besse,Caroline Caramella +28 more
TL;DR: It is suggested that HPD is more common with PD-1/PD-L1 inhibitors compared with chemotherapy in pretreated patients with NSCLC and is also associated with high metastatic burden and poor prognosis in patients treated with PD.
Journal ArticleDOI
Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.
Jordi Remon,Caroline Caramella,Cécile Jovelet,Ludovic Lacroix,Andrew R. J. Lawson,Sarah Smalley,Karen Howarth,Davina Gale,Emma Green,Vincent Plagnol,Nitzan Rosenfeld,David Planchard,M.V. Bluthgen,A. Gazzah,Chloe Pannet,Claudio Nicotra,Edouard Auclin,J-C. Soria,Benjamin Besse +18 more
TL;DR: Assessment of the efficacy of osimertinib when T790M status is determined in circulating cell-free tumour DNA (ctDNA) from blood samples in progressing advanced EGFR-mutant NSCLC patients found ctDNA from liquid biopsy can be used as a surrogate marker for T790m in tumour tissue.
Journal ArticleDOI
Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
TL;DR: New therapies with improved cerebral-spinal fluid penetration have been developed for subgroups of molecular selected patients indicating they could be promising therapeutic options for managing leptomeningeal disease.